How Tobacco Screening Works in Clinical Practice

Tobacco screening is the routine practice of asking patients whether they use tobacco products, then following up with advice, assessment, and treatment referrals as needed. The US Preventive Services Task Force gives this an “A” recommendation for all adults, its highest grade, meaning the evidence of benefit is strong enough that every clinician should be doing it at every opportunity.¹ The concept sounds simple, but putting it into practice raises a surprising number of questions about which tools to use, who gets missed, and what counts as “tobacco” in an era of vaping and smokeless products.

What Tobacco Screening Actually Looks Like in a Clinic

At its most basic, tobacco screening is a single question: “Do you use tobacco?” The widely used “5 A’s” framework builds out from there. A clinician Asks about tobacco use, Advises the user to quit, Assesses willingness to make a quit attempt, Assists with treatment, and Arranges follow-up. In busy primary care settings, a condensed version called Ask-Advise-Refer is more common, where the clinician identifies tobacco use, recommends quitting, and connects the patient with a cessation program or quitline rather than managing the quit attempt in-house. A pilot study of screening, brief intervention, and referral in smokers with HIV found the approach was feasible and acceptable even among people who were not actively trying to quit, producing meaningful reductions in daily cigarette counts and nicotine dependence scores.²

The USPSTF recommendation covers all adults and specifically includes pregnant people, though the guidance differs slightly. For nonpregnant adults, the recommendation is behavioral interventions plus FDA-approved pharmacotherapy such as nicotine replacement, bupropion, or varenicline. For pregnant people, the recommendation is limited to behavioral interventions, since the safety data on cessation medications during pregnancy is less settled.³

Gauging How Dependent Someone Is

Not every person who uses tobacco needs the same level of intervention. Someone who smokes two cigarettes on weekends is in a different situation from someone who lights up within five minutes of waking. Screening tools exist to sort this out quickly, and two stand out for their brevity and usefulness.

The Heaviness of Smoking Index is a two-item questionnaire that asks how many cigarettes a person smokes per day and how soon after waking they smoke their first one. A score of four or higher reliably identifies high nicotine dependence, and validation work has confirmed that this cutoff holds up well across different population subgroups.⁴ That second question, time to first cigarette, carries a lot of information on its own. Research has consistently linked earlier time to first cigarette with higher levels of tobacco-exposure biomarkers, greater likelihood of failing a quit attempt, and higher relapse rates, and these associations hold for both adults and adolescents even after accounting for how many cigarettes someone smokes per day.⁵

In a time-pressed clinical encounter, asking “How soon after waking do you smoke your first cigarette?” gives you a fast read on how hard quitting will be. If the answer is within half an hour, you are probably talking to someone who will need more intensive support than a pamphlet and a phone number.

When Self-Report Is Not Enough

Most tobacco screening relies on people honestly reporting their own use, and in general clinical settings, that works reasonably well. Studies comparing self-reported tobacco use to biochemical verification have found high concordance and low false-negative rates among adults in clinical trials.⁶ But there are specific populations and situations where self-report breaks down, and biochemical testing becomes much more important.

Cotinine, a metabolite of nicotine, is the most commonly used biomarker. It can be measured in urine, saliva, or blood. In smokers, average urine cotinine levels run above 1,000 ng/ml. In passive smokers (people who don’t smoke but are regularly exposed), levels are far lower but still clearly elevated compared to unexposed people.⁷ This sharp separation between groups is what makes cotinine useful for verification: there is rarely ambiguity about whether someone has been actively smoking.

Cotinine testing is not routine in most clinical encounters. It adds cost, requires a specimen, and in contexts where the goal is to help rather than to catch, it can feel adversarial. But in research studies, clinical trials, and certain prenatal care contexts, it serves as a reality check on what patients report.

Pregnancy and Underreporting

Pregnancy is the setting where the gap between self-report and biochemical reality is most studied and most concerning. About one in ten pregnant women who say they have quit smoking actually show biochemical evidence of continued smoking.⁸ That is the optimistic number. A study that tracked misclassification across trimesters using urine cotinine testing found much higher nondisclosure rates: roughly a third of women who identified as nonsmokers in early pregnancy had cotinine levels consistent with active tobacco use. The rate was highest in the first trimester, at about 35%, and lowest in the third trimester, at about 27%, suggesting some women genuinely quit as pregnancy progresses while others simply stop admitting to smoking.⁹

The stigma around smoking during pregnancy is intense, and the underreporting is understandable. But it creates a clinical blind spot. If a provider takes the self-report at face value, they miss an opportunity to offer help, and the pregnancy continues with unaddressed tobacco exposure. Some prenatal care programs now use cotinine screening specifically for this reason, framing it as a standard part of care rather than a lie-detector test.

The Vaping Problem

Traditional tobacco screening questions were designed for cigarettes and smokeless tobacco. When a provider asks “Do you use tobacco?” a teenager who vapes nicotine may honestly answer no, because they do not think of their e-cigarette as a tobacco product. This creates a real gap in screening accuracy.

One study tested a standard clinical brief screener and found it caught about 80% of adolescents with any past-year tobacco use but only 50% of those using e-cigarettes specifically.¹⁰ In other words, a coin flip. That is not a screening tool; it is a guess with extra steps. The researchers concluded that new measures specifically sensitive to e-cigarette use were needed.

Better tools do exist. The S2BI and BSTAD screening instruments, which ask about substance use frequency in a broader way, identified over 90% of adolescent nicotine vapers and virtually all cannabis vapers without needing separate vaping-specific questions.¹¹ The difference seems to be in how the questions are framed. Tools that ask about nicotine use or substance use more broadly do better than those that specifically ask about “tobacco,” because the word itself creates a conceptual loophole for e-cigarette users.

Integrating e-cigarette-specific assessment into electronic health records is another approach, though it has its own challenges. One group developed an E-Cigarette and Vaping Assessment Tool for the EHR but found that screening adolescents was particularly difficult due to competing priorities during clinical visits and limited provider awareness of the tool.¹² The tool exists, but getting it used consistently is a separate problem.

How Electronic Health Records Change the Game

The single biggest lever for improving tobacco screening rates is building prompts into the electronic health record. When the EHR reminds clinicians to ask about tobacco use, they ask. When it does not, many don’t, or at least not consistently.

Using EHRs to prompt screening and document tobacco status has been linked to dramatically higher odds of screening occurring at all. One analysis found that EHR-based screening prompts were associated with a 428% increase in screening odds at rural primary care practices and a 220% increase at urban ones.¹³ The rural boost was larger, likely because rural clinics had lower baseline rates and more room to improve. When EHRs also reminded clinicians of treatment guidelines, odds of patients receiving cessation treatment went up by about 68%, with no difference between rural and urban settings.

EHR prompts also matter downstream for lung cancer screening. Since eligibility for low-dose CT lung cancer screening depends partly on smoking history, having complete tobacco-use records in the chart is essential. After one health system implemented EHR prompts specifically designed to capture smoking history in enough detail to determine lung cancer screening eligibility, the odds of having a complete record, being identified as eligible, and having a scan ordered all went up significantly.¹⁴

The Connection to Lung Cancer Screening

Tobacco screening and lung cancer screening are distinct processes, but they feed into each other. Lung cancer screening with low-dose CT is recommended for adults in a high-risk window defined by age and cumulative smoking history. Without accurate tobacco screening data in the chart, eligible patients never get referred for the scan.

The evidence that low-dose CT screening saves lives in heavy smokers is strong. The landmark National Lung Screening Trial found a 20% reduction in lung cancer deaths among those screened with low-dose CT compared to those screened with standard chest X-ray.¹⁵ A later meta-analysis pooling data from eight trials found a 12% relative reduction in lung cancer death, a smaller but still meaningful number that reflects the broader range of study designs included.¹⁶

Despite these benefits, uptake of lung cancer screening remains low. A systematic review of disparities found that Black individuals and socioeconomically disadvantaged groups face barriers at every stage, from being identified as eligible to completing follow-up care after an abnormal finding.¹⁷ This makes thorough tobacco screening an equity issue, not just a clinical one. If your smoking history is not documented well enough to trigger a lung cancer screening referral, you may never get one.

Tobacco Use in People With Mental Illness

People with severe mental illness smoke at roughly two to three times the rate of the general population, depending on the diagnosis and country. A multi-country survey of mental health institutions in South Asia found current tobacco use rates among male patients ranging from about 35% in India to 58% in Pakistan. Only about 38% of tobacco users in those settings reported receiving advice to quit during a healthcare visit in the preceding year.¹⁸

In the US, outpatient psychiatry has historically been a setting where tobacco screening happens inconsistently. Research examining psychiatric visits found that current smoking was most often identified during encounters involving alcohol or drug-related diagnoses and those involving schizophrenia or psychosis.¹⁹ This suggests a pattern where clinicians ask about smoking when it fits their mental model of the patient’s diagnosis, rather than asking everyone regardless. Patients with depression or anxiety, who also smoke at elevated rates, may be getting screened less reliably.

The old myth that quitting smoking destabilizes psychiatric conditions has been thoroughly debunked. If anything, smoking cessation is associated with improvements in anxiety and depression. But the myth persists among some providers and patients, making it a barrier both to screening and to follow-through on treatment.

Screening Children for Secondhand Smoke Exposure

Children do not smoke, but they are exposed to tobacco through the adults around them, and screening for that exposure is a separate challenge with its own tools. Asking parents directly about household smoking is the most practical approach, but parents underreport for the same reasons pregnant women do: stigma and social desirability.

Research testing various screening questions for pediatric secondhand smoke exposure found that two items together performed well: “During the past 30 days, did you smoke cigarettes at all?” and “Has anyone, including yourself, smoked tobacco in your home in the past 7 days?” A positive answer to either one showed good specificity and sensitivity for identifying children with cotinine levels consistent with smoke exposure, and the results held up in a nationally representative sample.²⁰

For biochemical confirmation, serum cotinine in children is considered the gold standard, but what counts as “exposed” is not straightforward. A systematic review found that the cutoff values used to define secondhand smoke exposure in children under five varied enormously across studies, from 0.015 to 35 ng/ml, with no consensus on age-specific, sex-specific, or race-specific thresholds.²¹ That is a 2,000-fold range. Until standardized cutoffs are established, interpreting cotinine levels in young children requires more clinical judgment than the test alone can provide.

Does Tobacco Screening Actually Save Money?

The cost-effectiveness data on tobacco screening and brief intervention is about as good as it gets in preventive medicine. One analysis of a comprehensive primary care smoking treatment program found the cost came to roughly $630 per person who quit and about $900 per quality-adjusted life year gained.²² For context, interventions that cost less than $50,000 per quality-adjusted life year are generally considered cost-effective, and many widely accepted medical treatments cost far more than that. At under $1,000, tobacco screening and treatment is extraordinarily cheap per unit of health gained.

A broader modeling study that looked at repeated screening and brief counseling over a smoker’s lifetime estimated that when you factor in the healthcare costs prevented by the diseases people don’t develop, the intervention actually saves about $500 per smoker. That is not $500 per quitter; it is $500 per person who goes through the screening and brief intervention process, counting the many who do not quit on any given attempt.²³ The key insight is that even modest quit rates, in the range of 2 to 5% per attempt, add up when you keep screening and intervening at every visit over years. The lifetime quit rate in that model reached about 23% when repeated interventions were accounted for.

Who Gets Screened and Who Gets Missed

Tobacco screening is supposed to be universal, but in practice, some people are more likely to be asked than others. A study of two health systems found that about a third of identified smokers were never invited to participate in a cessation program. Clinics varied widely, with invitation rates ranging from 40% to 88%. Smokers who got invited tended to be older and either white or Black; younger patients and those from other racial groups were less likely to be reached.²⁴

On the encouraging side, when screening programs are designed with equity in mind, they can work well across demographic lines. An opt-out tobacco screening and treatment referral program in an oncology setting found that African American patients had the highest rates of tobacco use, program enrollment, and treatment engagement. Patients in the most socioeconomically deprived areas also enrolled at higher rates. And the six-month quit rate, about 22%, did not differ by race or deprivation level.²⁵ The opt-out design matters here: instead of waiting for a clinician to decide to bring up tobacco, every patient is screened automatically, and those who use tobacco are referred unless they actively decline. This removes the variability in who gets asked.

Workplace Screening and Beyond the Clinic

Tobacco screening is not confined to doctor’s offices. Worksite wellness programs have long included tobacco use identification as part of broader health risk assessments. The evidence suggests that screening alone does very little, but when paired with follow-up counseling and a menu of interventions, participation in cessation programs goes up and improvements are better maintained over time.²⁶ Screening identifies who might benefit; what happens after the screening is what determines whether anyone actually quits.

Qualitative research from low-resource settings in Mumbai illustrates the challenges of extending tobacco screening beyond well-funded health systems. Patients, practitioners, and policymakers all recognized the value of brief advice and counseling, but they identified barriers at every level. Patients described tobacco as embedded in their daily routines and social lives. Practitioners noted the difficulty of adding tobacco screening on top of existing workloads. Policymakers emphasized the need for uniform implementation strategies that could work across diverse clinical settings with different resource levels.²⁷ These are not problems unique to India. Any setting where clinicians are stretched thin and patients face economic insecurity will encounter similar obstacles.

Digital Tools and Emerging Approaches

The screening itself is increasingly digital: tablet-based questionnaires in waiting rooms, patient portal check-ins before appointments, and EHR-triggered prompts are all becoming standard. What comes after screening is also evolving. Mobile apps and AI-based tools for relapse prevention are a growing field. A review of currently available digital therapeutics found that systems using machine learning or automated conversational interfaces showed relapse-prediction accuracy above 70 to 80%, with good sensitivity and specificity.²⁸ These tools are not screening instruments in the traditional sense, but they extend the reach of what screening initiates. If a patient is identified as a tobacco user in the clinic, an app that monitors their risk of relapse in real time could make the difference between a quit attempt that sticks and one that unravels a week after the visit ends.

The gap between identifying a smoker and helping them successfully quit remains the central challenge. Screening is cheap, fast, and well supported by evidence. The harder part is what happens next, and digital tools are one way to keep the intervention going long after the patient leaves the exam room.